Novel binders derived from an albuminbinding domain scaffold targeting human prostate secretory protein 94 (PSP94)

References

[1] Ahmad JN, Li J, Biedermannova L, Kuchar M, Sipova H, Semeradtova A, Cerny J, Petrokova H, Mikulecky P, Polinek J (2012) Novel high-affinity binders of human interferon gamma derived from albumin-binding domain of protein G. Proteins 80(3): 774−789

[2] Anahi Franchi N, Avendano C, Molina RI, Tissera AD, Maldonado CA, Oehninger S, Coronel CE (2008) β-Microseminoprotein in human spermatozoa and its potential role in male fertility. Reproduction 136(2): 157−166

[3] Anklesaria JH, Jagtap DD, Pathak BR, Kadam KM, Joseph S, Mahale SD (2013) Prostate Secretory Protein of 94 amino acids (PSP94) binds to prostatic acid phosphatase (PAP) in human seminal plasma. PLoS One 8(3): e58631

[4] Annabi B, Currie JC, Bouzeghrane M, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Beliveau R (2006) Contribution of the 37-kDa laminin receptor precursor in the antimetastatic PSP94-derived peptide PCK3145 cell surface binding. Biochem Biophys Res Commun 346(1): 358−366

[5] FitzGerald LM, Zhang X, Kolb S, Kwon EM, Liew YC, Hurtado-Coll A, Knudsen BS, Ostrander EA, Stanford JL (2013) Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression. Hum Mutat 34(1): 149−156

[6] Gilbreth RN, Koide S (2012) Structural insights for engineering binding proteins based on non-antibody scaffolds. Curr Opin Struct Biol 22(4): 413−420

[7] Kuchar M, Vankova L, Petrokova H, Cerny J, Osicka R, Pelak O, Sipova H, Schneider B, Homola J, Sebo P (2014) Human interleukin-23 receptor antagonists derived from an albuminbinding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells. Proteins 82(6): 975−989

[8] Lazzeri M, Briganti A, Scattoni V, Lughezzani G, Larcher A, Gadda GM, Lista G, Cestari A, Buffi N, Bini V (2012) Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. J Urol 188(4): 1137−1143

[9] Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, Orr N, Yu K, Hutchinson A, Jacobs KB, Kraft P (2009) Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci USA 106(19): 7933−7938

[10] Manaskova-Postlerova P, Davidova N, Sulc M, Philimonenko A, Hozak P, Jonakova V (2011) Reproductive tissue expression and sperm localization of porcine beta-microseminoprotein. Cell Tissue Res 344(2): 341−353

[11] Mhatre DR, Mahale SD, Khatkhatay MI, Desai SS, Jagtap DD, Dhabalia JV, Tongaonkar HB, Desai MP, Dandekar SP, Varadkar AM (2014) Development of an ELISA for sPSP94 and utility of the sPSP94/sPSA ratio as a diagnostic indicator to differentiate between benign prostatic hyperplasia and prostate cancer. Clin Chim Acta 436: 256−262

[12] Nam RK, Reeves JR, Toi A, Dulude H, Trachtenberg J, Emami M, Daigneault L, Panchal C, Sugar L, Jewett MA (2006) A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol 175(4): 1291−1297

[13] Reeves JR, Dulude H, Panchal C, Daigneault L, Ramnani DM (2006) Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin Cancer Res 12(20 Pt 1): 6018−6022

[14] Velonas VM, Woo HH, Remedios CG, Assinder SJ (2013) Current status of biomarkers for prostate cancer. Int J Mol Sci 14(6): 11034−11060

[15] Yang JP, Finkelman MA, Clarke MW (1998) Detection of PSP94 and its specific binding sites in the prostate adenocarcinoma cell line LNCaP. J Urol 160(6 Pt 1): 2240−2244

RIGHTS & PERMISSIONS

2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.